Recent studies have shown that treatment with rHDL containing apoA-I as the main component improves kidney histology and function in multiple diabetic mouse models and can slow down the progression of DKD, specifically, with improvement in proteinuria, prevention of GFR decline, attenuation of glomerular tunica dilatation/glomerulosclerosis, ECM protein accumulation and renal fibrosis as well as inhibition of podocyte loss [222,223,224]. Here, APOA1 is linked to diabetic kidney disease.